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Summary
The 2012 World Heart Federation (WHF) criteria for echocardiographic diagnosis 
of rheumatic heart disease (RHD) identify that the finding of ‘pathological’ mitral 
regurgitation (MR) in a screened individual increases the likelihood of detecting underlying 
RHD. Cases of isolated ‘pathological MR’ are thus identified as ‘borderline RHD’. A large-
scale echocardiographic screening program (Echo in Africa) in South Africa has identified 
that inter-scallop separations of the posterior mitral valve leaflet (PMVL) can give rise to 
‘pathological’ MR. The authors propose that this entity in isolation should be identified 
and excluded from the WHF ‘borderline RHD’ category. In this case report, we present two 
examples of ‘pathological’ MR related to inter-scallop separation from the Echo in Africa 
image database. We further provide screening tips for the accurate identification of this 
entity.
Learning points:
 • Posterior mitral valve leaflet inter-scallop separations are an important entity to identify as a potential cause of 
haemodynamically insignificant yet WHF ‘pathological’ MR.
 • Cases of inter-scallop separations with ‘pathological’ MR remain an important finding in RHD screening and those 
without any other morphological features of RHD should be excluded from the WHF ‘borderline RHD’ group.
 • Careful interrogation of the mitral valve in both PSLAX and PSSAX views is required to identify the underlying 
mechanism of MR.
 • Further study is needed in our study population to describe the prevalence and clinical relevance of inter-scallop 
separations.
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Background
Rheumatic heart disease (RHD) is responsible for 
significant morbidity and mortality in developing nations 
and underserved communities in the developed world 
(1). Sub Saharan Africa has been identified as an area with 
endemic RHD with an estimated 10 per 1000 population 
living with RHD (2).
The consensus-derived diagnostic criteria established 
in 2012 – the ‘World Heart Federation criteria for 
echocardiographic diagnosis of rheumatic heart disease’ (3) 
– represent an important milestone in the standardization 
of diagnostic parameters and the reporting of RHD.
However, the criteria are potentially weakened by the 
incorporation of a non-specific Doppler-based evaluation 
of regurgitant valvular lesions that could erroneously 
include cases with ‘congenital MR’ into the ‘borderline 
RHD’ group (4, 5, 6, 7).
A large-scale RHD screening program in both high- 
and low-risk RHD communities in the Western Cape, 
South Africa (unpublished data from the Echo in Africa 
(EIA) program) has identified that a normal variant of 
the posterior mitral valve leaflet (PMVL) – so-called 
‘prominent posterior leaflet inter-scallop separation’ 
(5) – may be responsible for a proportion of screened 
cases identified as ‘borderline RHD’ with isolated WHF 
‘pathological’ MR.
These separations, ‘indentations’ or ‘slits’, have 
been described in anatomical cardiology texts dating 
back to the 1950s (8, 9, 10, 11). They are known to 
exclusively affect the PMVL with marked heterogeneity 
relating to their location, number (between 0 and 5 
separations in a single PMVL) and depth of excursion 
into the PMVL (8, 11). Victor & Nayak propose in their 
autopsy series that these separations are a normal 
finding in the PMVL and play an important role in 
allowing the PMVL to ‘change in contour and size during 
atrial and ventricular systole’ (11).
To the best of our knowledge, there is no 
echocardiographic data that highlight this entity and 
document its particular relevance to RHD screening.
Case presentation
We present two cases selected from the EIA database 
of ‘borderline RHD’ with isolated ‘pathological’ MR 
attributable to prominent inter-scallop separations of 
the PMVL. Both cases met all 4 Doppler criteria for WHF 
‘pathological’ MR.
Investigation
Participants in the Echo in Africa program are screened by 
experienced RHD sonographers using the General Electric 
(GE) Vivid I laptop unit. Screening studies are captured in 
accordance with a minimum standard dataset as stipulated 
by the British Society for Echocardiography (12).
Case 1 is a screening study obtained from an individual 
living in a high-risk RHD community (low socio-economic 
status (SES) and with no access to private medical care). 
Videos 1, 2, 3 and 4 have been selected from the initial 
screening study to demonstrate the relevant findings.
Video 1
Parasternal long axis view (PSLAX) demonstrating a 
normal mitral valve (normal anterior mitral valve leaflet 
(AMVL) thickness, no RHD-related restriction of either 
MV leaflets. View Video 1 at http://movie-usa.
glencoesoftware.com/video/10.1530/ERP-18-0010/video-1.
Video 2
PSLAX view with color Doppler demonstrating MR that 
measures 2.2 cm in length. The jet met the additional 
requirements to deem it pathological (seen in 2 views, 
CW maximum velocity >3 m/s and a pansystolic jet). View 
Video 2 at http://movie-usa.glencoesoftware.com/
video/10.1530/ERP-18-0010/video-2.
Video 3
Parasternal short axis (PSSAX) view of the mitral valve, 
demonstrating a PMVL inter-scallop separation in the P2 
position. View Video 3 at http://movie-usa.
glencoesoftware.com/video/10.1530/ERP-18-0010/video-3.
Video 4
PSSAX with color Doppler confirming a P2 inter-scallop 
separation as the underlying cause of the MR. View 
Video 4 at http://movie-usa.glencoesoftware.com/
video/10.1530/ERP-18-0010/video-4.
Case 2 is from an individual living in a low-risk RHD 
community (high SES with access to private medical care). 
Videos 5, 6, 7 and 8 have been selected from the initial 
screening study to demonstrate the relevant findings.
Video 5
Parasternal long axis view (PSLAX) demonstrating a 
normal mitral valve (normal anterior mitral valve leaflet 
(AMVL) thickness, no RHD-related restriction of either 
MV leaflets. View Video 5 at http://movie-usa.
glencoesoftware.com/video/10.1530/ERP-18-0010/video-5.
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Video 6
PSLAX view with color Doppler demonstrating MR that 
measured 2.2 cm in length. The jet met the additional 
requirements to deem it pathological (seen in 2 views, 
CW maximum velocity >3 m/s and a pansystolic jet). View 
Video 6 at http://movie-usa.glencoesoftware.com/
video/10.1530/ERP-18-0010/video-6.
Video 7
PSSAX view of the mitral valve, demonstrating a subtler 
case of an inter-scallop separation in the P2/P3 position. 
View Video 7 at http://movie-usa.glencoesoftware.com/
video/10.1530/ERP-18-0010/video-7.
Video 8
PSSAX with color Doppler confirming a P2/P3 inter-
scallop separation as the underlying cause of the MR. 
View Video 8 at http://movie-usa.glencoesoftware.com/
video/10.1530/ERP-18-0010/video-8.
Tips for the echocardiographic diagnosis of 
inter-scallop separations in screening
Parasternal long axis
 • Dynamic scanning with color Doppler is used to 
identify the segment of the PMVL where the regurgitant 
jet is seen to be maximal and thus coinciding with the 
inter-scallop separation. The so-called ‘parasternal 
sweep’ is performed by tilting the probe up (more 
lateral portion – P2/P1) and then tilting downwards 
(more medial portion – P2/P3) (Fig. 1).
 • Suspect an inter-scallop separation as a cause of MR 
particularly when the MR jet is centrally directed and 
shown to emanate from below the coaptation point 
of the PMVL with the anterior mitral valve leaflet 
(AMVL) (Video  9). This feature however cannot be 
solely relied upon as regurgitant jets can be posteriorly 
directed (Video 2) and can therefore mimic the classic 
‘pseudoprolapse’ mechanism of chronic rheumatic MR 
in terms of jet direction (Videos 10 and 11).
Video 9
A screened case from the EIA database with ‘pathological 
MR’ from an inter-scallop separation of the PMVL. This 
video from the PSLAX view with focused color Doppler 
over the MV demonstrates central MR with its origin 
below the coaptation point of the MV leaflets (i.e. body 
of the PMVL). View Video 9 at http://movie-usa.
glencoesoftware.com/video/10.1530/ERP-18-0010/video-9.
Video 10
PSLAX view demonstrating a rheumatic mitral valve with 
suggestive RHD-related restriction of the AMVL and 
PMVL. The A2 segment of the AMVL is seen to ‘prolapse’ 
past the P2 segment of the PMVL. This mechanism is 
more correctly termed ‘pseudoprolapse’ as the AMVL is 
in its normal position at end systole. The impression of 
A2 prolapse is rather thought to be related to PMVL 
systolic restriction with resultant malcoaptation of the 
PMVL and AMVL during systole. This generates the 
characteristic posteriorly directed jet of rheumatic MR. 
View Video 10 at http://movie-usa.glencoesoftware.com/
video/10.1530/ERP-18-0010/video-10.
Figure 1
Parasternal sweep: sweeping from commissure to 
commissure (tilting the echo probe from side to 
side in the PSLAX) with focused color Doppler 
over the MV will identify, which segment is likely 
to have an inter-scallop separation.
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Video 11
PSLAX view with focused color Doppler over the MV – 
this video demonstrates the characteristic posterior MR 
jet encountered in chronic rheumatic MR. View Video 11 
at http://movie-usa.glencoesoftware.com/video/10.1530/
ERP-18-0010/video-11.
Parasternal short axis
 • Tilt to view leaflet tips of PMVL without color – try to 
identify the separate scallops and the separations that 
demarcate them (Video  12). Inter-scallop separations 
are identified as visible linear defects extending a 
variable depth into the posterior leaflet from the 
coaptation line. The inter-scallop area is often seen to 
‘open up’ during diastole when the scallop edges part 
in this region.
 • Color Doppler is used to confirm site of regurgitation 
(often below coaptation line of the two mitral leaflets) 
(Video  13) The color jet origin is typically confined 
to the inter-scallop region and the jet origin spreads 
predominantly vertically down the height of the 
PMVL rather than across the coaptation line between 
the AMVL and PMVL.
Video 12
PSSAX view of a screened case from the EIA database 
with ‘pathological MR’. The screener should ensure that 
the leaflet tips are adequately sectioned to identify 
potential inter-scallop separation(s). This video 
demonstrates an inter-scallop separation in the P2/P3 
position. View Video 12 at http://movie-usa.
glencoesoftware.com/video/10.1530/ERP-18-0010/
video-12.
Video 13
PSSAX of the same case presented in Video 12: focused 
color Doppler over the MV confirms a P2 inter-scallop 
separation as the underlying cause of the MR. View 
Video 13 at http://movie-usa.glencoesoftware.com/
video/10.1530/ERP-18-0010/video-13.
Discussion
In this case report we describe a known anatomical 
feature of the PMVL, so-called inter-scallop separation, 
which can be attributed to cause WHF ‘pathological MR’ 
in screened cases from both a high- and low-risk RHD 
community.
Identifying alternative ‘congenital’ causes of MR 
is an important step in the screening process and 
specifically stipulated by the WHF in an attempt to 
curb misidentification of non-rheumatic cases. Included 
among these are congenital anomalies related to leaflet 
clefts or apparent clefts.
Among the mimics of mitral leaflet clefts are entities 
that can be readily differentiated from true clefts such as 
the trileaflet mitral valve. In this entity, the identification 
of an additional papillary muscle aids in diagnosis (13). 
True, isolated AMVL clefts (not related to atrio-ventricular 
septal defects) are a rare finding (14, 15), but due to an 
absence of anatomical scallops of the AMVL, these entities 
are not confused with inter-scallop separations and readily 
identified as congenital abnormalities.
The same does not hold true for cleft-like defects 
identified in the PMVL. As early as the 1950s, there 
was contention as to what constitutes the PMVL and 
importantly, no consistent anatomical nomenclature was 
agreed on to define its variable divisions (8, 10, 11, 16). 
This lack of agreement persists, and there is no consensus 
on what features differentiate the normal anatomical 
variant of an inter-scallop separation from a cleft or even 
whether a separation of the entities is warranted. Two 
strategies of identifying true clefts from among inter-
scallop separations have been to look at either the size 
of the defect or functional consequence thereof. A recent 
study describing the prevalence and impact of clefts in 
mitral valve prolapse (MVP) identified clefts as defects 
that extend >50% of the height of the posterior leaflet 
and are visible during systole and diastole (17). The 
authors conclude that these clefts may play an important 
role in the development and mechanism of prolapse 
but acknowledge that they likely reflect one end of the 
spectrum of normality, having also been identified in 
their control population (17).
In contrast to this, Wyss et al. propose that a cleft is 
defined as a ‘complete split up to the annulus and has some 
degree of regurgitation’ (18), choosing instead to incorporate 
a functional deficit into the definition.
The addition of this functional aspect does not appear 
to be strongly rooted in a fundamental difference in 
pathology identified, and it is our contention that PMVL 
clefts, something previously considered rare (19, 20, 21) 
is perhaps only one end of the spectrum of normal inter-
scallop separation (17).
This raises important challenges in the RHD screening 
environment. Whereas the impact of PMVL ‘clefts’ have 
been explored in cohorts with overt valve pathology, their 
role remains undefined in healthy asymptomatic children 
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undergoing RHD screening. Inter-scallop separation, 
a normal anatomical entity, has not been identified as 
a potential confounder in the current WHF diagnostic 
criteria. Consequently, if not recognized and excluded 
from analysis, could falsely increase the prevalence of 
‘borderline RHD’ detected in any RHD screening program. 
In addition, failure to exclude these cases could further 
distort the findings of long-term studies documenting the 
outcome of ‘borderline RHD’ as progression of MR from 
this entity remains unexplored (22, 23, 24).
Therefore, in the absence of compelling RHD-related 
morphological changes of the AMVL or the aortic valve 
(AV), we do not advocate diagnosing cases with RHD where 
the mechanism of WHF pathological MR is clearly related 
to an inter-scallop separation. To what extent these cases 
are currently inflating the size of the Borderline group is 
an important question that needs to be further studied.
Given the ubiquitous nature of PMVL inter-scallop 
separations, it is inevitable that screening programs will 
encounter individuals with true RHD features of their 
mitral valve in addition to their normal variation of the 
PMVL (inter-scallop separation with MR). What remains 
unclear is what specific features of the mitral valve in 
cases of ‘presumed normal PMVL variants’ will alert the 
screener to consider a diagnosis of concurrent RHD.
Further research is required to describe the prevalence 
and natural history of inter-scallop separations in both 
high- and low-risk RHD populations and the effect that 
the RHD process has on this underlying normal PMVL 
variant.
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